{"id":809847,"date":"2025-02-06T08:21:35","date_gmt":"2025-02-06T13:21:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/"},"modified":"2025-02-06T08:21:35","modified_gmt":"2025-02-06T13:21:35","slug":"transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/","title":{"rendered":"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>No significant safety or dose limiting\u00a0toxicities reported<\/li>\n<li>PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results<\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">BOSTON<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 6, 2025<\/span><\/span> \/PRNewswire\/ &#8212; TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate.\u00a0 The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic (PK) data and is monitoring Cohort 3 as preliminary data becomes available.\u00a0The dose administered to patients in the third cohort is approximately double the dose administered in the second cohort.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2583692\/TransCode_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2583692\/TransCode_Logo.jpg\" title=\"Logo (PRNewsfoto\/TransCode Therapeutics, Inc.)\" alt=\"Logo (PRNewsfoto\/TransCode Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Several patients in the first and second cohort remain on study for continued treatment, receiving additional doses of TTX-MC138 over cycles of approximately 28 days each. \u00a0No significant safety or dose limiting toxicities have been reported in any of the trial&#8217;s nine patients.\u00a0 Analyses of PK data and pharmacodynamic (PD) activity from Cohorts 1 and 2 is ongoing. To date, the analyses suggest that TTX-MC138 demonstrates a PK\/PD profile consistent with preclinical results and results from TransCode&#8217;s previous Phase 0 clinical trial.\u00a0 Specifically, results from Cohort 1 confirmed the Phase 0 observation that TTX-MC138\u00a0shows evidence of pharmacodynamic activity in the presence of high baseline expression of miR-10b, reaching a 66% inhibition at 24 hours after infusion, similar to that seen in the Phase 0 trial. Additionally, TTX-MC138 activity increased with the escalated dose administered in Cohort 2 and was consistent at subsequent administrations\u00a0suggesting a favorable pharmacokinetic profile.<\/p>\n<p>\n        <b>About TTX-MC138<\/b>\n      <\/p>\n<p>TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode&#8217;s 2023 Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug candidate, suggesting a broad therapeutic window for TTX-MC138.\u00a0\u00a0<\/p>\n<p>\n        <b>About the Trial\u00a0<\/b>\u00a0<\/p>\n<p>TransCode&#8217;s Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study designed to generate critical data to support evaluation of the safety and tolerability of TTX-MC138 in patients with a variety of metastatic solid cancers.\u00a0 While not an endpoint, the trial may provide early evidence of clinical activity of TTX-MC138. The trial comprises an initial dose-escalation stage followed by a dose-expansion stage. The primary objective of the dose-escalation stage is to evaluate the safety and tolerability of escalating dose levels of TTX-MC138. In the dose-expansion stage, the safety, tolerability and anti-tumor activity of TTX-MC138 will be further evaluated in certain tumor types selected based on preliminary results from the dose-escalation phase.<\/p>\n<p>Further information is available at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4356896-1&amp;h=3787975796&amp;u=http%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;a=www.clinicaltrials.gov\" target=\"_blank\" rel=\"nofollow\">www.clinicaltrials.gov<\/a>\u00a0 NCT Identifier: (NCT06260774).<\/p>\n<p>\n        <b>About TransCode Therapeutics<\/b>\u00a0<\/p>\n<p>TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company&#8217;s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.\u00a0<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\u00a0<\/p>\n<p>This release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing, conduct and results of the Phase 1 clinical trial, statements about microRNAs and their involvement in cancer, and statements concerning the therapeutic potential of TransCode&#8217;s TTX-MC138 and other therapeutic candidates. Any forward-looking statements in this press release are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode&#8217;s preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode&#8217;s financial condition and its need to obtain additional funding to support its business activities, including TransCode&#8217;s ability to continue as a going concern; risks associated with the timing and outcome of TransCode&#8217;s planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode&#8217;s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode&#8217;s dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode&#8217;s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in TransCode&#8217;s Annual Report on Form 10-K for the year ended <span class=\"xn-chron\">December 31, 2023<\/span>, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law.\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE13317&amp;sd=2025-02-06\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial-302369681.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial-302369681.html<\/a><\/p>\n<p>SOURCE  TransCode Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE13317&amp;Transmission_Id=202502060800PR_NEWS_USPR_____NE13317&amp;DateId=20250206\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire No significant safety or dose limiting\u00a0toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON , Feb. 6, 2025 \/PRNewswire\/ &#8212; TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate.\u00a0 The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic (PK) data and is monitoring Cohort 3 as preliminary data becomes available.\u00a0The dose administered to patients in the third cohort &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809847","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire No significant safety or dose limiting\u00a0toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON , Feb. 6, 2025 \/PRNewswire\/ &#8212; TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate.\u00a0 The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic (PK) data and is monitoring Cohort 3 as preliminary data becomes available.\u00a0The dose administered to patients in the third cohort &hellip; Continue reading &quot;TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T13:21:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2583692\/TransCode_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial\",\"datePublished\":\"2025-02-06T13:21:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/\"},\"wordCount\":947,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2583692\\\/TransCode_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/\",\"name\":\"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2583692\\\/TransCode_Logo.jpg\",\"datePublished\":\"2025-02-06T13:21:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2583692\\\/TransCode_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2583692\\\/TransCode_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - Market Newsdesk","og_description":"PR Newswire No significant safety or dose limiting\u00a0toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON , Feb. 6, 2025 \/PRNewswire\/ &#8212; TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate.\u00a0 The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic (PK) data and is monitoring Cohort 3 as preliminary data becomes available.\u00a0The dose administered to patients in the third cohort &hellip; Continue reading \"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-06T13:21:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2583692\/TransCode_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial","datePublished":"2025-02-06T13:21:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/"},"wordCount":947,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2583692\/TransCode_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/","name":"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2583692\/TransCode_Logo.jpg","datePublished":"2025-02-06T13:21:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2583692\/TransCode_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2583692\/TransCode_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-in-phase-1-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809847"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809847\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}